CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 2,229 enrolled
Drug / intervention
LABA based treatment: indacaterol +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01794780
NCT01794780Phase 4Completed

A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator

Novartis Pharmaceuticals·interventional·Posted Feb 20, 2013·Updated Sep 26, 2019

In Brief

A Phase 4 clinical trial evaluating LABA based treatment: indacaterol, LAMA based treatment: tiotropium, and 4 other interventions for COPD. Completed, enrolled 2,229 participants across 2 sites.

Detailed Summary

This multi-center study is designed to describe natural history of disease, treatment and health care products in physician-diagnosed COPD patients who require adding daily maintenance therapy in real world. The study planned to enroll 550 patients in Indacaterol group and 9450 patients in non- Indacaterol group, a total of 10,000 patients. Enrollment was stopped at 2253 patients due to low recruitment in indacaterol group. Finally a total of 2229 patients were analyzed in full analysis set. A total of 2253 patients entered into the database, of which 24 patients were exclude during the data review meetings, because they did not met the inclusion/exclusion criteria. Hence a total of 2229 patients enrolled successfully.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 20, 2013
Enrollment StartFeb 5, 2013
Primary CompletionMay 25, 2015
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 13.4 years ago

Interventions

LABA based treatment: indacateroldrug

LABA based treatment: indacaterol

LAMA based treatment: tiotropiumdrug

LAMA based treatment: tiotropium

LABA/ICS based treatment: salmeterol/fluticasonedrug

LABA/ICS based treatment: salmeterol/fluticasone

LABA/ICS based treatment: budesonide/formoteroldrug

LABA/ICS based treatment: budesonide/formoterol

theophylline based treatmentdrug

theophylline based treatment

Other treatmentdrug

non-long-acting bronchodilators for COPD treatment, such treatments were classified as "other treatments"